Lung cancer patients with anaplastic lymphoma kinase rearrangement lose affiliation with labor market at diagnosis.

The main purpose of the present study was to investigate the labor market affiliation of NSCLC patients in long-term treatment as well as overall survival and incidence/prevalence. Nationwide retrospective study of all patients with NSCLC in Denmark diagnosed between 2012 and 2018. During the study period NSCLC patients had a median overall survival of 44.

Temporal trends and regional variability in BRAF and KRAS genetic testing in Denmark (2010-2022): Implications for precision medicine.

Objective: This study aims to evaluate the developments in the testing of Kirsten Rat Sarcoma viral oncogene homolog (KRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) mutations across different cancer types and regions in Denmark from 2010 to 2022.

Study Design And Setting: Using comprehensive data from the Danish health registries, we linked molecular test results from the Danish Pathology Registry with cancer diagnoses from the Danish National Patient Registry between 2010 and 2022. We assessed the frequency and distribution of KRAS and BRAF mutations across all cancer types, years of testing, and the five Danish regions.

Clinical outcomes of + non-small cell lung cancer in Denmark.

Background: Real-world clinical outcomes of anaplastic lymphoma kinase positive (+) non-small cell lung cancer (NSCLC) patients vary. This study aimed to investigate the treatment and clinical outcomes of all + NSCLC patients in Denmark in the period 2011-2018, regardless of disease stage.

Materials And Methods: A national pathology database with complete coverage was used to identify + NSCLC patients diagnosed between 2011 and 2018.

KRAS G12C mutated advanced non-small cell lung cancer (NSCLC): Characteristics, treatment patterns and overall survival from a Danish nationwide observational register study.

Objectives: We aimed to characterize the advanced NSCLC population in terms of KRAS G12C prevalence, patient characteristics, and survival outcomes after the introduction of immunotherapies.

Materials And Methods: We identified adult patients diagnosed with advanced NSCLC between January 1, 2018 and June 30, 2021 using the Danish health registries. Patients were grouped by mutational status (any KRAS mutation, KRAS G12C, and KRAS/EGFR/ALK wildtype [Triple WT]).

[Medical treatment of lung cancer].

Lung cancer causes most cancer-related deaths in the western world. In Denmark, over 4,700 cases of lung cancer are diagnosed annually. The medical treatment of lung cancer has undergone a significant development over the past 20 years.

Monte Carlo calculations support organ sparing in Deep-Inspiration Breath-Hold intensity-modulated radiotherapy for locally advanced lung cancer.

Background And Purpose: Studies indicate that Deep-Inspiration Breath-Hold (DIBH) is advantageous over Free-Breathing (FB) for locally advanced lung cancer radiotherapy. However, these studies were based on simplified dose calculation algorithms, potentially critical due to the heterogeneous nature of the lung region. Using detailed Monte-Carlo (MC) calculations, a comparative study of DIBH vs.

Antiangiogenic therapy for breast cancer.

Angiogenesis is an important component of cancer growth, invasion and metastasis. Therefore, inhibition of angiogenesis is an attractive strategy for treatment of cancer. We describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimal use of these agents for the treatment of breast cancer.